React4Life

React4life is a biotech company that develops technologies (Organ-On-Chip) that help pharmaceutical companies, university researchers, and testing companies achieve their goals, such as testing new drugs and vaccines and developing personalized therapies.

The OOC arena is a huge opportunity, as regulatory bodies (European Commission, FDA) are pushing to replace or reduce the use of animals in biomedical research; furthermore, the market is experiencing hype, similar to what happened with the Internet in 1994.

During the development of a new drug by the pharmaceutical company, the lack of an adequate experimental model to emulate human biology leads to high costs (1-2 B$) and long times (up to 12 years): in fact, current laboratory tests (in vitro) and animal testing (in vivo) do not represent human complexity, leading to 80% of cases to a selection of drugs to be brought into the incorrect clinical phase.

Basic researchers also need realistic models to study diseases and advance basic knowledge.

The organ on chip represents the most advanced, reliable and efficient technology for reproducing human biology in the laboratory.

React4life has patented MIVO, an organ-on-chip that recreates the organ-to-organ connection, offering high reliability and reduced animal use.